TACC3 Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cervical Squamous Cell Carcinoma1
FGFR3::TACC3 Fusion	Fexagratinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID9241 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic
Diffuse Astrocytoma1
FGFR3::TACC3 Fusion	Fexagratinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID9242 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Cervical Squamous Cell Carcinoma1

FGFR3::TACC3 Fusion

Fexagratinib

Predictive

Supports Sensitivity Response

submitted

EID9241

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

Diffuse Astrocytoma1

FGFR3::TACC3 Fusion

Fexagratinib

Predictive

Supports Sensitivity Response

submitted

EID9242

Esophageal Squamous Cell Carcinoma1
FGFR3::TACC3 Fusion	Unspecified therapy	Predictive	B	Does Not Support Sensitivity Response	3	rejected	EID2962 In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC) PMID 27771611 · Mizukami et al., 2017 · Open in CIViC	civic

Esophageal Squamous Cell Carcinoma1

FGFR3::TACC3 Fusion

Unspecified therapy

Predictive

Does Not Support Sensitivity Response

rejected

EID2962

In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC)

PMID 27771611 · Mizukami et al., 2017 · Open in CIViC

civic

Gastric Adenocarcinoma1
FGFR3::TACC3 Fusion	Futibatinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID11638 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic

Gastric Adenocarcinoma1

FGFR3::TACC3 Fusion

Futibatinib

Predictive

Supports Sensitivity Response

submitted

EID11638

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

civic

Glioblastoma1
FGFR3::TACC3 Fusion	Erdafitinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID13165 In the phase II NCI-MATCH EAY131-K2 trial, two patients with WHO grade IV IDH1/2-wildtype glioblastoma harboring FGFR3 fusions experienced progression-free survival exceeding 168 days during erdafitin… (full text at CIViC) PMID 38603650 · Gong et al., 2024 · Open in CIViC	civic

Glioblastoma1

FGFR3::TACC3 Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID13165

In the phase II NCI-MATCH EAY131-K2 trial, two patients with WHO grade IV IDH1/2-wildtype glioblastoma harboring FGFR3 fusions experienced progression-free survival exceeding 168 days during erdafitin… (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

civic

Malignant Neoplasm2
FGFR3::TACC3 Fusion	Erdafitinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1919 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic
FGFR3::TACC3 Fusion AND FGFR3 N540K	Erdafitinib + FutibatinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID12706 Ba/F3 cells expressing the FGFR3::TACC3 fusion with or without the N540K mutation were treated with multiple FGFR inhibitors, including erdafitinib and futibatinib. In parental Ba/F3 cells, the IC50 v… (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC	civic

Malignant Neoplasm2

FGFR3::TACC3 Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID1919

Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 … (full text at CIViC)

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

civic

FGFR3::TACC3 Fusion AND FGFR3 N540K

Erdafitinib + FutibatinibSubstitutes

Predictive

Supports Resistance

accepted

EID12706

Ba/F3 cells expressing the FGFR3::TACC3 fusion with or without the N540K mutation were treated with multiple FGFR inhibitors, including erdafitinib and futibatinib. In parental Ba/F3 cells, the IC50 v… (full text at CIViC)

PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC

civic

Renal Pelvis Urothelial Carcinoma1
FGFR3::TACC3 Fusion	Fexagratinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID9227 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC	civic

Renal Pelvis Urothelial Carcinoma1

FGFR3::TACC3 Fusion

Fexagratinib

Predictive

Supports Sensitivity Response

submitted

EID9227

PMID 32463741 · Chae et al., 2020 · Open in CIViC

civic

Transitional Cell Carcinoma1
FGFR3::TACC3 Fusion	Infigratinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID6409 In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC	civic

Transitional Cell Carcinoma1

FGFR3::TACC3 Fusion

Infigratinib

Predictive

Supports Sensitivity Response

accepted

EID6409

In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC)

PMID 29848605 · Pal et al., 2018 · Open in CIViC

civic

Adrenal Carcinoma1unmapped disease
FGFR3::TACC3 Fusion AND FGFR2::CCDC6 Fusion	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID4861 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic

Adrenal Carcinoma1unmapped disease

FGFR3::TACC3 Fusion AND FGFR2::CCDC6 Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID4861

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

civic

Evidence by cancer (10 items)

Clinical significance (0)